Door-to-balloon time and in-hospital mortality in patients with ST-elevation myocardial infarction: A network experience in a province in northwest Tuscany, Italy;Tempo door-to-balloon e mortalità intraospedaliera nel paziente con infarto miocardico acuto con sopraslivellamento del tratto ST: Esperienza di una rete integrata in una provincia dell'area nord-ovest della Toscana

Giornale Italiano di Cardiologia

Volumn 11, Issue 5, 2010, Pages 386-392

  Paradossi, Umberto ^a   Palmieri, Cataldo ^a   Trianni, Giuseppe ^a   Ravani, Marcello ^a   Vaghetti, Marco ^a   Rizza, Antonio ^a   Gianetti, Jacopo ^a   Cardullo, Simona ^a   Chabane, Hakim ^a   Maffei, Stefano ^a   Berti, Sergio ^a  

^a Ospedale del Cuore   (Italy)

Author keywords

Door to balloon time; Myocardial infarction; Percutaneous coronary intervention

Indexed keywords

AGED; ARTICLE; BALLOON; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; GEOGRAPHY; GOLD STANDARD; HEART HEMODYNAMICS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION; ADULT; EMERGENCY; ITALY; MIDDLE AGED; MYOCARDIAL INFARCTION; TIME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; EMERGENCIES; FEMALE; HOSPITAL MORTALITY; HUMANS; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TIME FACTORS; YOUNG ADULT;

EID: 77952369978     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.
2. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622
3. Grines CL. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Primary angioplasty - the strategy of choice. N Engl J Med 1996; 335: 1313-1316
4. Jacobs AK. Primary angioplasty for acute myocardial infarction - is it worth the wait? N Engl J Med 2003; 349: 798-800.
5. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322 (Pubitemid 124000789)
6. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996; 27: 1646-1655
7. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (<2h), intermediate (2-4h) and late (>4h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J 2002; 23: 550-557
8. De Luca G, Ernst N, Zijlstra F, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004; 43: 1363-1367 (Pubitemid 38496339)
9. Brodie BR, Hansen C, Stuckey TD, et al. Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. J Am Coll Cardiol 2006; 47: 289-295
10. Federazione Italiana di Cardiologia-Società Italiana di Cardiologia Invasive. Documento di Consenso: La rete interospedaliera per l'emergenza coronarica. Ital Heart J 2005; 6 (Suppl 6): 55-265.
11. Schiller NB, Acquatella H, Ports TA, et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation 1979; 60: 547-555
12. Alonso DR, Scheidt S, Post M, Killip T. Pathophysiology of cardiogenic shock: quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation 1973; 48: 588-596
13. McNamara RL, Wang Y, Herrin J, et al, for the NRMI Investigators. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2006; 47: 2180-2186 (Pubitemid 43810139)
14. Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med 2006; 355: 2308-2320
15. Khot UN, Johnson ML, Ramsey C, et al. Emergency department physician activation of the catheterization laboratory and immediate transfer to an immediately available catheterization laboratory reduce door-to-balloon time in ST-elevation myocardial infarction. Circulation 2007; 116: 67-76.
16. Jollis JG, Roettig ML, Aluko AO, et al, for the Reperfusion of Acute Myocardial Infarction in North Carolina Emergency Departments (RACE) Investigators. Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA 2007; 298: 2371-2380
17. Le May MR, So DY, Dionne R, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2008; 358: 231-240
18. Ting HH, Rihal CS, Gersh BJ, et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 2007; 116: 729-736
19. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology: Eur Heart J 2008; 29: 2909-2945
20. Van de Werf FJ. Fine-tuning the selection of a reperfusion strategy. Circulation 2006; 114: 2002-2003
21. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339: 753-770
22. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618-627
23. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682